Edwards Lifesciences Inc. (NYSE:EW) is looking to finish today’s session on a up note, with shares rising nearly 5 percent after European officials approved a third size of the company’s Sapien XT transcatheter aortic heart valve.
The CE Mark brings the 29mm valve to much of Europe and extends the reach of Edward’s Ascendra transapical delivery system — a minimally invasive surgical technique implanting valves through incisions between the ribs rather than a patients’ sternum.